Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
Science Translational Medicine (2017) - Comments
doi: 10.1126/scitranslmed.aal5148  issn: 1946-6234  issn: 1946-6242  pubmed: 28566428 

Chaoyang Sun, Yong Fang, Jun Yin, Jian Chen, Zhenlin Ju, Dong Zhang, Xiaohua Chen, Christopher P. Vellano, Kang Jin Jeong, Patrick Kwok-Shing Ng, Agda Karina B. Eterovic, Neil H. Bhola, Yiling Lu, Shannon N. Westin, Jennifer R. Grandis, Shiaw-Yih Lin, Kenneth L. Scott, Guang Peng, Joan Brugge, Gordon B. Mills